Satoris : Collaboration to Validate Early Alzheimer's Test

April 1, 2008 — Satoris, Inc., a molecular diagnostics company focused on developing blood-based tests for Alzheimer's disease, will shortly begin a collaborative study with the Mayo Foundation for Medical Education and Research (Mayo Clinic) to validate the utility of plasma biomarkers for earl detection of mild to moderate Alzheimer's disease. These biomarkers may also predict the progression of patients from a state of mild cognitive impairment to Alzheimer's. Satoris researchers first reported the utility of Alzheimer's�related biomarkers in the November, 2007 edition of the peer-reviewed scientific journal, Nature Medicine. In the reported study, researchers analyzed 259 stored blood samples, comparing those from individuals with presymptomatic to late-stage Alzheimer's disease with those from individuals without the disease... Satoris' Press Release -

Satoris and First Blood Test to Diagnose Alzheimer's Disease

October 15, 2007 - — A team of international researchers reported they have identified a group of cell-signaling proteins found in blood that serve as a unique “voiceprint” that can not only be used to diagnose Alzheimer’s disease*, but also classify and predict presymptomatic individuals who will eventually develop the memory-robbing disorder. The study describing the new test appears in this week’s online version of the scientific journal, Nature Medicine. “Our technology enables us to ‘listen’ to the chatter of cells communicating with each other and determine if there’s anything abnormal,” said Tony Wyss-Coray, Ph.D., a lead scientist in the study, and a co-founder of San Francisco-based Satoris Inc. ... Satoris ' Press Release-